# Treace Medical Concepts, Inc.: financial statements, quarterly

TMCI · Nasdaq · CIK 1630627 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/tmci.md) · [Financials](/companies/tmci/financials.md) · [Filings](/companies/tmci/filings.md) · [Insiders](/companies/tmci/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/tmci/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [40.8](/filings/0000950170-24-121460.md) | [62.2 d](/filings/0001193125-26-079167.md) | [51.1](/filings/0000950170-25-066953.md) | [44.5](/filings/0000950170-25-105059.md) | [45.1](/filings/0001193125-25-269556.md) | [68.7 d](/filings/0001193125-26-079167.md) | [52.6](/filings/0001193125-26-213322.md) | [47.4](/filings/0001630627-26-000018.md) | [50.2](/filings/0001193125-25-269556.md) | [62.5 d](/filings/0001193125-26-079167.md) | [47.2](/filings/0001193125-26-213322.md) | [45.4](/filings/0001630627-26-000018.md) |
| Cost of revenue | $m | [8.0](/filings/0000950170-24-121460.md) | [11.5 d](/filings/0001193125-26-079167.md) | [10.1](/filings/0000950170-25-066953.md) | [8.8](/filings/0000950170-25-105059.md) | [9.0](/filings/0001193125-25-269556.md) | [13.2 d](/filings/0001193125-26-079167.md) | [10.7](/filings/0001193125-26-213322.md) | [9.6](/filings/0001630627-26-000018.md) | [10.5](/filings/0001193125-25-269556.md) | [12.1 d](/filings/0001193125-26-079167.md) | [9.8](/filings/0001193125-26-213322.md) | [9.8](/filings/0001630627-26-000018.md) |
| Gross profit | $m | [32.8](/filings/0000950170-24-121460.md) | [50.7 d](/filings/0001193125-26-079167.md) | [41.0](/filings/0000950170-25-066953.md) | [35.7](/filings/0000950170-25-105059.md) | [36.1](/filings/0001193125-25-269556.md) | [55.5 d](/filings/0001193125-26-079167.md) | [41.9](/filings/0001193125-26-213322.md) | [37.8](/filings/0001630627-26-000018.md) | [39.7](/filings/0001193125-25-269556.md) | [50.4 d](/filings/0001193125-26-079167.md) | [37.4](/filings/0001193125-26-213322.md) | [35.6](/filings/0001630627-26-000018.md) |
| Research and development | $m | [4.4](/filings/0000950170-24-121460.md) | [4.2 d](/filings/0001193125-26-079167.md) | [5.3](/filings/0000950170-25-066953.md) | [5.2](/filings/0000950170-25-105059.md) | [5.0](/filings/0001193125-25-269556.md) | [5.2 d](/filings/0001193125-26-079167.md) | [5.6](/filings/0001193125-26-213322.md) | [5.5](/filings/0001630627-26-000018.md) | [4.7](/filings/0001193125-25-269556.md) | [4.5 d](/filings/0001193125-26-079167.md) | [4.6](/filings/0001193125-26-213322.md) | [4.4](/filings/0001630627-26-000018.md) |
| Operating income | $m | [(17.8)](/filings/0000950170-24-121460.md) | [(6.8) d](/filings/0001193125-26-079167.md) | [(19.0)](/filings/0000950170-25-066953.md) | [(21.4)](/filings/0000950170-25-105059.md) | [(15.1)](/filings/0001193125-25-269556.md) | [(0.2) d](/filings/0001193125-26-079167.md) | [(15.6)](/filings/0001193125-26-213322.md) | [(17.0)](/filings/0001630627-26-000018.md) | [(15.7)](/filings/0001193125-25-269556.md) | [(5.9) d](/filings/0001193125-26-079167.md) | [(17.2)](/filings/0001193125-26-213322.md) | [(15.0)](/filings/0001630627-26-000018.md) |
| Interest expense | $m | [1.3](/filings/0000950170-24-121460.md) | [1.3 d](/filings/0001193125-26-079167.md) | [1.3](/filings/0000950170-25-066953.md) | [1.3](/filings/0000950170-25-105059.md) | [1.3](/filings/0001193125-25-269556.md) | [1.3 d](/filings/0001193125-26-079167.md) | [1.3](/filings/0001193125-26-213322.md) | [1.3](/filings/0001630627-26-000018.md) | [1.3](/filings/0001193125-25-269556.md) | [1.4 d](/filings/0001193125-26-079167.md) | [1.6](/filings/0001193125-26-213322.md) | [1.6](/filings/0001630627-26-000018.md) |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(17.5)](/filings/0000950170-24-121460.md) | [(6.3) d](/filings/0001193125-26-079167.md) | [(18.7)](/filings/0001193125-25-269556.md) | [(21.2)](/filings/0001193125-25-269556.md) | [(15.4)](/filings/0001193125-25-269556.md) | [(0.5) d](/filings/0001193125-26-079167.md) | [(15.9)](/filings/0001630627-26-000018.md) | [(17.4)](/filings/0001630627-26-000018.md) | [(16.3)](/filings/0001193125-25-269556.md) | [(9.4) d](/filings/0001193125-26-079167.md) | [(18.0)](/filings/0001630627-26-000018.md) | [(15.9)](/filings/0001630627-26-000018.md) |
| Diluted EPS | $ per share | [(0.28)](/filings/0000950170-24-121460.md) | not reported | [(0.30)](/filings/0000950170-25-066953.md) | [(0.34)](/filings/0000950170-25-105059.md) | [(0.25)](/filings/0001193125-25-269556.md) | not reported | [(0.25)](/filings/0001193125-26-213322.md) | [(0.28)](/filings/0001630627-26-000018.md) | [(0.26)](/filings/0001193125-25-269556.md) | not reported | [(0.28)](/filings/0001193125-26-213322.md) | [(0.24)](/filings/0001630627-26-000018.md) |
| Basic EPS | $ per share | [(0.28)](/filings/0000950170-24-121460.md) | not reported | [(0.30)](/filings/0000950170-25-066953.md) | [(0.34)](/filings/0000950170-25-105059.md) | [(0.25)](/filings/0001193125-25-269556.md) | not reported | [(0.25)](/filings/0001193125-26-213322.md) | [(0.28)](/filings/0001630627-26-000018.md) | [(0.26)](/filings/0001193125-25-269556.md) | not reported | [(0.28)](/filings/0001193125-26-213322.md) | [(0.24)](/filings/0001630627-26-000018.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [7.3](/filings/0000950170-23-062068.md) | [13.0](/filings/0000950170-25-029029.md) | [9.3](/filings/0000950170-24-054480.md) | [18.2](/filings/0000950170-24-091787.md) | [12.1](/filings/0000950170-24-121460.md) | [11.4](/filings/0001193125-26-079167.md) | [13.4](/filings/0000950170-25-066953.md) | [8.1](/filings/0000950170-25-105059.md) | [7.7](/filings/0001193125-25-269556.md) | [10.7](/filings/0001630627-26-000018.md) | [9.5](/filings/0001193125-26-213322.md) | [12.6](/filings/0001630627-26-000018.md) |
| Current assets | $m | [187](/filings/0000950170-23-062068.md) | [198](/filings/0000950170-25-029029.md) | [187](/filings/0000950170-24-054480.md) | [172](/filings/0000950170-24-091787.md) | [158](/filings/0000950170-24-121460.md) | [161](/filings/0001193125-26-079167.md) | [149](/filings/0000950170-25-066953.md) | [148](/filings/0000950170-25-105059.md) | [138](/filings/0001193125-25-269556.md) | [132](/filings/0001630627-26-000018.md) | [123](/filings/0001193125-26-213322.md) | [120](/filings/0001630627-26-000018.md) |
| Total assets | $m | [240](/filings/0000950170-23-062068.md) | [252](/filings/0000950170-25-029029.md) | [243](/filings/0000950170-24-054480.md) | [226](/filings/0000950170-24-091787.md) | [213](/filings/0000950170-24-121460.md) | [217](/filings/0001193125-26-079167.md) | [206](/filings/0000950170-25-066953.md) | [206](/filings/0000950170-25-105059.md) | [197](/filings/0001193125-25-269556.md) | [191](/filings/0001630627-26-000018.md) | [184](/filings/0001193125-26-213322.md) | [181](/filings/0001630627-26-000018.md) |
| Current liabilities | $m | [33.2](/filings/0000950170-23-062068.md) | [45.0](/filings/0000950170-25-029029.md) | [47.0](/filings/0000950170-24-054480.md) | [44.4](/filings/0000950170-24-091787.md) | [38.3](/filings/0000950170-24-121460.md) | [34.9](/filings/0001193125-26-079167.md) | [33.2](/filings/0000950170-25-066953.md) | [41.9](/filings/0000950170-25-105059.md) | [40.9](/filings/0001193125-25-269556.md) | [30.6](/filings/0001630627-26-000018.md) | [34.5](/filings/0001193125-26-213322.md) | [41.5](/filings/0001630627-26-000018.md) |
| Total liabilities | $m | [103](/filings/0000950170-23-062068.md) | [114](/filings/0000950170-25-029029.md) | [116](/filings/0000950170-24-054480.md) | [114](/filings/0000950170-24-091787.md) | [108](/filings/0000950170-24-121460.md) | [104](/filings/0001193125-26-079167.md) | [101](/filings/0000950170-25-066953.md) | [109](/filings/0000950170-25-105059.md) | [107](/filings/0001193125-25-269556.md) | [103](/filings/0001630627-26-000018.md) | [107](/filings/0001193125-26-213322.md) | [113](/filings/0001630627-26-000018.md) |
| Long-term debt | $m | [52.9](/filings/0000950170-23-062068.md) | [53.0](/filings/0000950170-25-029029.md) | [53.1](/filings/0000950170-24-054480.md) | [53.2](/filings/0000950170-24-091787.md) | [53.2](/filings/0000950170-24-121460.md) | [53.3](/filings/0001193125-26-079167.md) | [53.4](/filings/0000950170-25-066953.md) | [53.5](/filings/0000950170-25-105059.md) | [53.5](/filings/0001193125-25-269556.md) | [55.6](/filings/0001630627-26-000018.md) | [55.8](/filings/0001193125-26-213322.md) | [56.0](/filings/0001630627-26-000018.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001193125-26-079167.md) | [0.0](/filings/0000950170-25-066953.md) | [1.1](/filings/0000950170-25-105059.md) | [1.8](/filings/0001193125-25-269556.md) | [1.7](/filings/0001630627-26-000018.md) | [1.8](/filings/0001193125-26-213322.md) | [3.2](/filings/0001630627-26-000018.md) |
| Shareholders' equity | $m | [138](/filings/0000950170-24-121460.md) | [138](/filings/0001193125-26-079167.md) | [126](/filings/0001193125-25-269556.md) | [112](/filings/0001193125-25-269556.md) | [105](/filings/0001193125-25-269556.md) | [113](/filings/0001630627-26-000018.md) | [105](/filings/0001630627-26-000018.md) | [97.6](/filings/0001630627-26-000018.md) | [89.2](/filings/0001193125-25-269556.md) | [87.3](/filings/0001630627-26-000018.md) | [77.2](/filings/0001630627-26-000018.md) | [67.7](/filings/0001630627-26-000018.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: not reported
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(9.5) d](/filings/0000950170-24-121460.md) | [0.5 d](/filings/0001193125-26-079167.md) | [(7.2)](/filings/0000950170-25-066953.md) | [(13.9) d](/filings/0000950170-25-105059.md) | [(11.8) d](/filings/0001193125-25-269556.md) | [(4.2) d](/filings/0001193125-26-079167.md) | [4.2](/filings/0001193125-26-213322.md) | [(3.1) d](/filings/0001630627-26-000018.md) | [(9.1) d](/filings/0001193125-25-269556.md) | [(8.0) d](/filings/0001193125-26-079167.md) | [7.2](/filings/0001193125-26-213322.md) | [(4.7) d](/filings/0001630627-26-000018.md) |
| Capital expenditure | $m | [3.5 d](/filings/0000950170-24-121460.md) | [2.2 d](/filings/0001193125-26-079167.md) | [3.9](/filings/0000950170-25-066953.md) | [1.7 d](/filings/0000950170-25-105059.md) | [2.9 d](/filings/0001193125-25-269556.md) | [3.1 d](/filings/0001193125-26-079167.md) | [3.5](/filings/0001193125-26-213322.md) | [4.8 d](/filings/0001630627-26-000018.md) | [2.8 d](/filings/0001193125-25-269556.md) | [2.4 d](/filings/0001193125-26-079167.md) | [3.1](/filings/0001193125-26-213322.md) | [2.2 d](/filings/0001630627-26-000018.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [55.4](/filings/0000950170-23-062068.md) | [58.7](/filings/0000950170-24-054480.md) | [61.4](/filings/0000950170-24-091787.md) | [61.6](/filings/0000950170-24-121460.md) | [61.8](/filings/0000950170-25-066953.md) | [62.1](/filings/0000950170-25-105059.md) | [62.2](/filings/0001193125-25-269556.md) | [62.7](/filings/0001193125-26-213322.md) | [63.0](/filings/0001630627-26-000018.md) | [63.5](/filings/0001193125-25-269556.md) | [64.6](/filings/0001193125-26-213322.md) | [65.0](/filings/0001630627-26-000018.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 65,034,552 at 2026-07-31, from the cover of the [10-Q filed 2026-08-07](/filings/0001630627-26-000018.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.